Open Journal of Depression

Volume 2, Issue 4 (November 2013)

ISSN Print: 2169-9658   ISSN Online: 2169-9674

Google-based Impact Factor: 1.69  Citations  

A Review of the Serotonin-Norepinephrine Reuptake Inhibitors: Pharmacologic Aspects and Clinical Implications for Treatment of Major Depressive Disorder and Associated Painful Physical Symptoms

HTML  Download Download as PDF (Size: 165KB)  PP. 54-63  
DOI: 10.4236/ojd.2013.24011    5,450 Downloads   11,435 Views  Citations

ABSTRACT

Background: Depression is characterized by low mood, low self-esteem, and loss of interest or pleasure. Painful physical symptoms (PPS) associated with depression have a negative impact on the probability of remission. Because both norepinephrine and serotonin are involved with the central regulation of pain, the serotonin-norepinephrine reuptake inhibitors (SNRIs) may have more success than the selective serotonin reuptake inhibitors (SSRIs) in impacting PPS as well as the core emotional symptoms of depression. Methods: Published preclinical and clinical data on the SNRIs (i.e., milnacipran, venlafaxine, and duloxetine) have been reviewed, paying special attention to the differentiation of the pharmacological aspects of the SNRIs. The efficacy and safety results on depression and associated PPS have also been summarized. Results: Each of the SNRIs has different profiles regarding the inhibition of binding to human serotonin and norepinephrine uptake transporters and clinical pharmacokinetics. All SNRIs have data for alleviating the core symptoms of depression; duloxetine and venlafaxine show efficacy for PPS associated with depression. There are also differences in tolerability and adverse events profiles. Conclusions: Although all SNRIs have the same dual mechanism of action for the treatment of depression, they have different pharmacologic profiles that may impact clinical outcomes.

Share and Cite:

Alev, L. , Lenox-Smith, A. , Altin, M. and Dueñas, H. (2013) A Review of the Serotonin-Norepinephrine Reuptake Inhibitors: Pharmacologic Aspects and Clinical Implications for Treatment of Major Depressive Disorder and Associated Painful Physical Symptoms. Open Journal of Depression, 2, 54-63. doi: 10.4236/ojd.2013.24011.

Cited by

[1] Evaluation of Flibanserin Safety: Comparison with Other Serotonergic Medications
2019
[2] Recent Studies on Anti-Depressant Bioactive Substances in Selected Species from the Genera Hemerocallis and Gladiolus: A Systematic Review
2019
[3] Duloxetine: the pharmacological and clinical profile of a drug from the group of serotonin and noradrenaline reuptake inhibitors
2018
[4] Duloksetyna–profil farmakologiczny i kliniczny leku z grupy inhibitorów zwrotnego wychwytu serotoniny i noradrenaliny
2018
[5] Treatment of Pain with Antidepressants
Klinik Psikofarmakoloji Bulteni, 2015
[6] Biogenic Amines and the Amino Acids GABA and Glutamate: Relationships with Pain and Depression
Pain in Psychiatric Disorders, 2015
[7] Normas de prescrição e utilização racional de antidepressivos
2015

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.